

MEA Nasal Spray Market - Industry Trends and Forecast to 2030

Market Report | 2023-03-01 | 164 pages | Data Bridge Market Research

AVAILABLE LICENSES:

- Single User License \$3500.00
- Corporate Users License \$4200.00

Report description:

The Middle East and Africa nasal spray market is projected to register a CAGR of 5.4% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation

Middle East and Africa Nasal Spray Market, By Product Type (Decongestion Nasal Spray, Steroid Nasal Spray, Salt Water Solution/Saline Nasal Spray, and Others), Container Design (Pump Bottles and Pressurized Canisters), Dosage Form (Multi Dose, Unit/Single Dose, and Bi Dose), Therapeutic Class (Antihistamine, Nasal Steroid, Mast Cell Inhibitor, and Anticholinergic), Application (Nasal Congestion, Allergic and Non-Allergic Rhinitis, Central Nervous System Disorders, Vaccination, and Others), Prescription/Availability (Over The Counter and Prescribed), End User (Home Care Settings, Hospitals, Clinics, and Community Health Care), Country (South Africa, Saudi Arabia, UAE, and Rest of Middle East and Africa) Industry Trends and Forecast to 2030

Some of the major factors contributing to the growth of the Middle East and Africa nasal spray market are:

- Rise in the therapeutic application of the nasal spray
- Increase in the demand for nasal sprays for allergic diseases and pandemics such as COVID-19

Market Players

Some of the major market players operating in the Middle East and Africa nasal spray market are:

- EMERGENT
- Cipla Inc.
- Sandoz International GmbH (A Part of Novartis)
- Aytu Health (A subsidiary of Aytu BioPharma, Inc.)
- Bayer AG
- GlaxoSmithKline plc.
- Assertio Therapeutics, Inc.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Aurena Laboratories.
- J Pharmaceuticals
- St. Renatus.
- Ultratech India Limited
- Catalent, Inc.
- Teva Pharmaceuticals USA, Inc. (A subsidiary of Teva Pharmaceutical Industries Ltd)
- Pfizer Inc.
- Viatris Inc.
- LEEFORD HEALTHCARE LTD
- Aishwarya Group

Table of Contents:

TABLE OF CONTENTS

1 INTRODUCTION	22
1.1 OBJECTIVES OF THE STUDY	22
1.2 MARKET DEFINITION	22
1.3 OVERVIEW	22
1.4 LIMITATIONS	24
1.5 MARKETS COVERED	24
2 MARKET SEGMENTATION	26
2.1 MARKETS COVERED	26
2.2 GEOGRAPHICAL SCOPE	27
2.3 YEARS CONSIDERED FOR THE STUDY	28
2.4 CURRENCY AND PRICING	28
2.5 DBMR TRIPOD DATA VALIDATION MODEL	29
2.6 MULTIVARIATE MODELLING	32
2.7 PRODUCT TYPE LIFELINE CURVE	32
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS	33
2.9 DBMR MARKET POSITION GRID	34
2.10 MARKET END USER COVERAGE GRID	35
2.11 VENDOR SHARE ANALYSIS	36
2.12 SECONDARY SOURCES	37
2.13 ASSUMPTIONS	37
3 EXECUTIVE SUMMARY	38
4 PREMIUM INSIGHTS	41
4.1 PORTER'S FIVE FORCES MODEL	42
4.2 PESTEL ANALYSIS	43
5 INDUSTRY INSIGHTS: MIDDLE EAST & AFRICA NASAL SPRAY MARKET	44
5.1 INDUSTRY INSIGHTS	44
6 REGULATIONS: MIDDLE EAST & AFRICA NASAL SPRAY MARKET	45
7 MARKET OVERVIEW	46
7.1 DRIVERS	48
7.1.1 INCREASE IN INFECTION AND ALLERGIC CASES	48
7.1.2 RISING PREVALENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA	48
7.1.3 EFFECTIVENESS OVER OTHER FORMS OF DRUG DELIVERY	49
7.1.4 IMPROVING PATIENT COMPLIANCE AND ACCEPTABILITY	50

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

7.2 RESTRAINTS	51
7.2.1 PRODUCT RECALLS	51
7.2.2 ADVERSE EFFECTS OF USING NASAL SPRAYS	52
7.3 OPPORTUNITIES	53
7.3.1 NEW RISING DEMAND FOR SELF-ADMINISTRATIVE DRUG DELIVERY	53
7.3.2 EXPANDING THERAPEUTIC APPLICATIONS FOR NASAL SPRAYS	53
7.3.3 STRATEGIC INITIATIVES TAKEN BY KEY MARKET PLAYERS	54
7.4 CHALLENGES	54
7.4.1 REGULATORY HURDLES	54
7.4.2 ADDICTION TO NASAL SPRAY	55
8 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY PRODUCT TYPE	56
8.1 OVERVIEW	57
8.2 DECONGESTION NASAL SPRAY	60
8.3 STEROID NASAL SPRAY	61
8.4 SALT WATER SOLUTION/SALINE NASAL SPRAY	62
8.5 OTHERS	63
9 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY CONTAINER DESIGN	64
9.1 OVERVIEW	65
9.2 PUMP BOTTLES	68
9.3 PRESSURIZED CANISTERS	69
10 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY DOSAGE FORM	70
10.1 OVERVIEW	71
10.2 MULTI DOSE	74
10.3 UNIT/SINGLE DOSE	75
10.4 BI DOSE	76
11 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS	78
11.1 OVERVIEW	79
11.2 ANTIHISTAMINE	82
11.3 NASAL STEROIDS	83
11.4 MAST CELL INHIBITOR	84
11.5 ANTICHOLINERGIC	85
12 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY APPLICATION	86
12.1 OVERVIEW	87
12.2 NASAL CONGESTION	90
12.3 ALLERGIC AND NON-ALLERGIC RHINITIS	91
12.4 CENTRAL NERVOUS SYSTEM DISORDERS	92
12.5 VACCINATION	93
12.6 OTHERS	94
13 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY	95
13.1 OVERVIEW	96
13.2 PRESCRIBED	99
13.3 OVER THE COUNTER	100
14 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY END USER	102
14.1 OVERVIEW	103
14.2 HOME CARE SETTINGS	106
14.3 HOSPITALS	107
14.4 CLINICS	108

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

14.5 COMMUNITY HEALTH CARE	109
15 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY REGION	110
15.1 MIDDLE EAST AND AFRICA	111
15.1.1 SOUTH AFRICA	118
15.1.2 UAE	120
15.1.3 SAUDI ARABIA	122
15.1.4 REST OF MIDDLE EAST & AFRICA	124
16 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, COMPANY LANDSCAPE	125
16.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA	125
17 SWOT ANALYSIS	126
18 COMPANY PROFILE	127
18.1 GLAXOSMITHKLINE PLC.	127
18.1.1 COMPANY SNAPSHOT	127
18.1.2 REVENUE ANALYSIS	127
18.1.3 COMPANY SHARE ANALYSIS	128
18.1.4 PRODUCT PORTFOLIO	128
18.1.5 RECENT DEVELOPMENTS	128
18.2 PFIZER INC.	130
18.2.1 COMPANY SNAPSHOT	130
18.2.2 REVENUE ANALYSIS	130
18.2.3 COMPANY SHARE ANALYSIS	131
18.2.4 PRODUCT PORTFOLIO	131
18.2.5 RECENT DEVELOPMENTS	131
18.3 EMERGENT	133
18.3.1 COMPANY SNAPSHOT	133
18.3.2 REVENUE ANALYSIS	133
18.3.3 COMPANY SHARE ANALYSIS	134
18.3.4 PRODUCT PORTFOLIO	134
18.3.5 RECENT DEVELOPMENT	134
18.4 SANDOZ INTERNATIONAL GMBH (A PART OF NOVARTIS)	135
18.4.1 COMPANY SNAPSHOT	135
18.4.2 REVENUE ANALYSIS	135
18.4.3 COMPANY SHARE ANALYSIS	136
18.4.4 PRODUCT PORTFOLIO	136
18.4.5 RECENT DEVELOPMENT	136
18.5 CATALENT, INC.	137
18.5.1 COMPANY SNAPSHOT	137
18.5.2 REVENUE ANALYSIS	137
18.5.3 COMPANY SHARE ANALYSIS	138
18.5.4 PRODUCT PORTFOLIO	138
18.5.5 RECENT DEVELOPMENTS	138
18.6 AYTU HEALTH (A SUBSIDIARY OF AYTU BIOPHARMA, INC.)	140
18.6.1 COMPANY SNAPSHOT	140
18.6.2 REVENUE ANALYSIS	140
18.6.3 PRODUCT PORTFOLIO	141
18.6.4 RECENT DEVELOPMENTS	141
18.7 AISHWARYA GROUP	142

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

18.7.1 COMPANY SNAPSHOT	142
18.7.2 PRODUCT PORTFOLIO	142
18.7.3 RECENT DEVELOPMENTS	142
18.8 ASSERTIO THERAPEUTICS, INC.	143
18.8.1 COMPANY SNAPSHOT	143
18.8.2 REVENUE ANALYSIS	143
18.8.3 PRODUCT PORTFOLIO	144
18.8.4 RECENT DEVELOPMENT	144
18.9 AURENA LABORATORIES.	145
18.9.1 COMPANY SNAPSHOT	145
18.9.2 PRODUCT PORTFOLIO	145
18.9.3 RECENT DEVELOPMENTS	145
18.10 BAYER AG	147
18.10.1 COMPANY SNAPSHOT	147
18.10.2 REVENUE ANALYSIS	147
18.10.3 COMPANY SHARE ANALYSIS	148
18.10.4 PRODUCT PORTFOLIO	148
18.10.5 RECENT DEVELOPMENTS	148
18.11 CIPLA INC.	150
18.11.1 COMPANY SNAPSHOT	150
18.11.2 REVENUE ANALYSIS	150
18.11.3 PRODUCT PORTFOLIO	151
18.11.4 RECENT DEVELOPMENT	151
18.12 J PHARMACEUTICALS.	152
18.12.1 COMPANY SNAPSHOT	152
18.12.2 PRODUCT PORTFOLIO	152
18.12.3 RECENT DEVELOPMENTS	152
18.13 LEEFORD HEALTHCARE LTD	153
18.13.1 COMPANY SNAPSHOT	153
18.13.2 PRODUCT PORTFOLIO	153
18.13.3 RECENT DEVELOPMENTS	153
18.14 ST. RENATUS.	154
18.14.1 COMPANY SNAPSHOT	154
18.14.2 PRODUCT PORTFOLIO	154
18.14.3 RECENT DEVELOPMENTS	154
18.15 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD)	155
18.15.1 COMPANY SNAPSHOT	155
18.15.2 REVENUE ANALYSIS	155
18.15.3 PRODUCT PORTFOLIO	156
18.15.4 RECENT DEVELOPMENTS	156
18.16 ULTRATECH INDIA LIMITED	157
18.16.1 COMPANY SNAPSHOT	157
18.16.2 PRODUCT PORTFOLIO	157
18.16.3 RECENT DEVELOPMENTS	157
18.17 VIATRIS INC.	158
18.17.1 COMPANY SNAPSHOT	158
18.17.2 REVENUE ANALYSIS	158

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

18.17.3 COMPANY SHARE ANALYSIS	159
18.17.4 PRODUCT PORTFOLIO	159
18.17.5 RECENT DEVELOPMENT	159
19 QUESTIONNAIRE	160
20 RELATED REPORTS	164

MEA Nasal Spray Market - Industry Trends and Forecast to 2030

Market Report | 2023-03-01 | 164 pages | Data Bridge Market Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$3500.00
	Corporate Users License	\$4200.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-09"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com